A comparative study of multi-omics integration tools for cancer driver gene identification and tumour subtyping

Anita Sathyanarayanan, Rohit Gupta, Erik W. Thompson, Dale R. Nyholt, Denis C. Bauer and Shivashankar H. Nagaraj

Abstract

Oncogenesis and cancer can arise as a consequence of a wide range of genomic aberrations including mutations, copy number alterations, expression changes and epigenetic modifications encompassing multiple omics layers. Integrating genomic, transcriptomic, proteomic and epigenomic datasets via multi-omics analysis provides the opportunity to derive a deeper and holistic understanding of the development and progression of cancer. There are two primary approaches to integrating multi-omics data: multi-staged (focused on identifying genes driving cancer) and meta-dimensional (focused on establishing clinically relevant tumour or sample classifications). A number of ready-to-use bioinformatics tools are available to perform both multi-staged and meta-dimensional integration of multi-omics data. In this study, we compared nine different integration tools using real and simulated cancer datasets. The performance of the multi-staged integration tools were assessed at the gene, function and pathway levels, while meta-dimensional integration tools were assessed based on the sample classification performance. Additionally, we discuss the influence of factors such as data representation, sample size, signal and noise on multi-omics data integration. Our results provide current and much needed guidance regarding selection and use of the most appropriate and best performing multi-omics integration tools.

Key words: multi-omics data; cancer; multi-staged integration; meta-dimensional integration; tools evaluation
Introduction

Alterations in the genetic make-up of a cell, such as mutations, copy number aberrations and epigenetic changes, can all drive the development of cancer [1]. Copy number aberrations, which involve the gain or loss of genomic DNA, contribute to oncogenesis and tumour progression by activating oncogenes or inactivating tumour suppressor genes [2]. Epigenetic mechanisms including methylation of cytosine bases play crucial roles in regulating gene expression during normal mammalian development. However, disruption of such regulatory mechanisms can cause hypermethylation or hypomethylation of gene promoter regions and can lead to silencing of critical tumour suppressor functions [3].

Despite these well-understood mechanisms, two major challenges remain for the studies of oncogenesis. The first challenge is the identification of genes and aberrations that serve as drivers for disease development, which is complicated by the evolutionary nature of the disease and the presence of passenger aberrations that do not contribute to disease development [4]. Identification of such genetic modulating factors can shed vital light on the underlying molecular mechanisms of disease. The second challenge is the stratification of samples or patients to discover clinically relevant molecular subtypes or treatment groups that can aid in improved patient prognosis and treatments. Conventional approaches to identify driver genes involve performing differential analyses using individual ‘omics’ datasets (such as identification of differentially expressed genes or methylated regions) [5], while approaches to identify relevant patient or disease subtypes involve concatenation of the individual omics datasets followed by classification using techniques such as Random Forests [6] or clustering of clusters obtained from individual omics datasets [7]. However, such analyses fail to provide insight into the interactions between the different regulatory systems encapsulated by different omics data types.

Multi-omics data integration allows the joint analysis of multiple omics datasets to provide a global view of the biological system and offers insights into the nature of the interactions between the different dataset layers. As cancer is a heterogeneous genetic disease, it is imperative that such multi-omics data integrations be performed in order to fully appreciate the complex inter-layer regulatory interactions governing the development and progression of this disease. Decreasing costs and technological advancement have enabled the multi-platform sequencing of thousands of tumours by consortia such as International Cancer Genome Consortium [8] and The Cancer Genome Atlas (TCGA) [9], driving a shift towards integrative multi-omics investigations of cancer.

Multi-omics integration strategies commonly employed to address the aforesaid challenges can broadly be classified into two types: multi-staged and meta-dimensional integrative approaches [10]. Multi-staged integration (also known as linear integration or sequential integration) is based on the linear hypothesis that variations in DNA lead to changes in gene expression levels, which in turn cause protein expression changes leading to diseases or phenotypic changes [11]. This approach models the relationship between two given omics data types as linear and hierarchical. The objective of this approach is to uncover cause-effect links (cis relationships), such as the effects of copy number aberration on the expression of the affected gene. Tools that employ multi-staged integration approaches perform gene-centric integration in order to uncover the potential driver genes and help understand the effects of the interplay between different gene regulatory levels on oncogenesis and cancer progression. There are numerous ready-to-use tools available which employ this approach, including CNAmet [12], iGC [13], PLRS [14], Oncodrive-CIS [15] and MethylMix [16].

Meta-dimensional integration (or simultaneous integration) is based on the hypothesis that interactions between the multiple biomolecular layers are non-hierarchical and complex [17]. This approach involves the simultaneous fusion of information derived from two or more omics data types and is commonly applied for problems such as tumour subtype discovery [18–20], biomarker identification [21] and the exploration of perturbed signalling pathways [22]. The integration is performed at sample level, and commonly used tools include SNF [23], BCC [24], iClusterPlus [25] and mixOmics [26].

Given the increasing availability of multi-omics datasets and the continuous development of analytical approaches and objectives, novel multi-omics integration tools are continuously being developed, and selection of the most appropriate and best performing integration tool from the numerous tools available can be a tedious and time-consuming task. Although previous comparative studies have investigated the performance of multi-omics integration tools, they have focused only on either the multi-staged or the meta-dimensional approaches and often failed to investigate the effects of gene (or feature) selection [27], influence of dataset size [28] and multi-class classification [29]. To bridge these knowledge gaps, in this article we present an overview of both the multi-staged and meta-dimensional integration tools currently available and conduct a systematic evaluation of these tools based on their performance. The multi-staged integration tools were evaluated based on their ability to identify cancer-associated genes, functional Gene Ontology (GO) terms and relevant pathways, while the meta-dimensional integration tools were evaluated based on their sample classification performance. Overall, our study is intended to aid users in the selection of tools for multi-omics integrative analyses.

Methods

Five multi-staged (CNAmet, iGC, PLRS, Oncodrive-CIS and MethylMix) and four meta-dimensional (SNF, BCC, iClusterPlus and mixOmics) tools were compared in this study and are summarized in the following sections and in Tables 1 and 2, respectively.

Multi-staged integration tools

This study assessed the performance of the CNAmet, iGC, PLRS, Oncodrive-CIS and MethylMix tools designed to carry out the multi-staged integration. A generalized workflow implemented in these tools to achieve integration and identify driver genes involves quantification of the strength of the cause and effect association between aberration in the DNA (copy number and methylation aberration) and mRNA expression at the gene level, using a statistical approach followed by correction for multiple hypothesis testing in order to identify the statistically significant genes. The statistical approaches include variations of linear regression techniques [50], Student’s t-tests [13] and correlation tests [16].

While iGC, PLRS and Oncodrive-CIS tools attempt to discover the genes that have dysregulated expression due to copy number change by integrating copy number and gene expression data, the MethylMix tool integrates methylation and gene expression data to identify the genes for which expression is influenced by
Table 1. Summary of multi-staged integration tools used in this study

| Tool       | Omics data | Input                                                                 | Output                                                                 | Method                                                                 | Reference |
|------------|------------|----------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|-----------|
| CNAmet     | CN, ME and GE | Gene-level CN and/or ME as binary matrices and GE matrix              | Weights, scores and associated P-values, and FDR for each gene           | Independent association of the omics using signal-to-noise ratio weights followed by combining weights to obtain a score | [12]      |
| iGC        | CN and GE   | Gene-level segmented or thresholded CN and GE matrices                | List of genes for which expression is driven by amplification and deletion with associated P- and FDR values | Student’s t-test with unequal variance                                  | [13]      |
| PLRS       | CN and GE   | Gene-level GE, CN, thresholded CN with CN call probabilities (optional) matrices | Spline coefficients of the model fitted for the genes, P-values and FDR values | Piecewise linear regression splines                                   | [14]      |
| Oncodrive-CIS | CN and GE | Gene-level GE matrix and thresholded CN                               | Scores for each gene that represent the bias towards expression dysregulation due to copy number change | Estimation of impact of CN change on GE followed by estimation of standard scores of the impact in tumour and normal samples and finally combining the standard scores | [15]      |
| MethylMix  | ME and GE   | Probe-level or gene-level ME and gene-level GE matrices              | List of transcriptionally predictive and differentially methylated genes | Linear regression followed by modelling using beta mixture model        | [16]      |

CN, copy number; GE, gene expression; ME, methylation.

Table 2. Summary of meta-dimensional integration tools used in this study

| Tool       | Omics data    | Input                                                                 | Output                                                                 | Method                                                                 | Reference |
|------------|---------------|----------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|-----------|
| SNF        | Any omics     | Matrices of the omics data                                          | Cluster assignments of samples                                         | Weighted similarity network fusion                                     | [23]      |
| BCC        | GE, ME, miRNA, proteomics | Matrices of the omics data                                          | Adherence values and cluster assignments of samples for multi-omics clustering and individual omics clustering | Bayesian clustering based on Dirichlet mixture model                    | [24]      |
| iClusterPlus | Any omics    | Matrices of the omics data                                          | Cluster assignments of samples and multi-omics gene signature          | Joint modelling followed by feature selection using lasso              | [25]      |
| mixOmics   | Any omics     | Matrices of the omics data and the labels associated with samples    | Prediction of class labels for test data and multi-omics gene signature | Sparse generalized canonical correlation analysis. Feature selection using lasso | [26]      |

GE, gene expression; ME, methylation.

methylation status. The CNAmet tool is capable of modelling both the combined as well as independent effects of a given gene’s copy number and methylation status on its expression. In this study, we used the CNAmet tool to identify the independent effects of the copy number and methylation aberrations on the gene expression. Table 1 summarizes the details regarding the reviewed multi-staged integration tools (see Supplementary Data section for more details).

Meta-dimensional integration tools

The meta-dimensional integration tools assessed in this study include the SNF, BCC, iClusterPlus and mixOmics. These tools employ one or more mathematical techniques including matrix factorization, correlation, Bayesian, network and transformation [31, 32], for the simultaneous integration of multiple omics data types.

The SNF tool integrates multi-omics data using transformation-based network fusions. Briefly, each omics data type is transformed into a network wherein the nodes represent samples and weighted edges represent the similarity between the samples. Next, these individual networks are fused into a single network using message-passing theory method [33], where high similarity edges between the samples in one or more omics data types are retained, and inconsistent low similarity edges are removed. Finally, the subtypes are estimated using a spectral clustering method. However, the SNF tool does
not provide the users with the information on the important features responsible for the observed subtypes. The BCC tool performs Bayesian consensus clustering based on an extended Dirichlet mixture model for multiple omics data types. This method assumes that there is a separate clustering observed in each omics data type and that these clusters adhere loosely to an overall clustering. Although this method provides information regarding similarity between clusters of independent omics data types and the consensus clustering through adherence parameter (ω), this method does not convey the important genes associated with the clustering. The iClusterPlus tool performs model-based matrix factorization integration. Here, each omics data type is decomposed into a components factor and a loading factor based on different modelling assumptions for different omics data types. The components factor represents the common latent cancer subtypes, and the loading factor represents the gene features. The important features are selected using lasso regularization [34], and the clusters are identified using a K-means clustering algorithm. The mixOmics tool also employs a matrix factorization-based method, which extends the sparse generalized canonical correlation analysis to a supervised classification problem. Here, the correlation between the components factors is maximized and projected to a smaller dimensional space, and the important features are selected by lasso regularization [34]. The SNF, BCC and iClusterPlus tools perform an unsupervised classification of the integrated multi-omics data that are effective for data exploration and discovery of novel subtypes, while the mixOmics tool performs supervised classification in which the sample subtype is also provided as an input during integration. Table 2 summarizes the details on these meta-dimensional tools (see Supplementary Data section for more details).

Datasets used for multi-staged integration tool analyses

Level 3 TCGA data pertaining to four cancers, mesothelioma [35], colon [36], pancreatic [37] and melanoma [38], processed and hosted by the UCSC Xena [39] and the firebrowse (http://firebrowse.org) databases, were used in this study. These cancers were selected as they have varying sample size and are widely studied. The following omics data were downloaded for each cancer (refer to Supplementary Table S1 for more details):

- Copy number variation: Gene-level GISTIC 2.0 [40] segmented and thresholded copy number variation downloaded from the UCSC Xena database. While the segmented data contain the copy number estimates, the thresholded copy number data contain the thresholded estimates, i.e. −2, −1, 0, 1 and 2, representing homozygous deletion, single copy deletion, diploid normal copy, low-level copy number amplification and high-level copy number amplification, respectively.
- Gene expression: Gene-level transcription estimates, as in log2(x+1) transformed RSEM [41] normalized expression counts downloaded from the UCSC Xena database.
- DNA methylation: Gene-level mean beta values were downloaded from the firebrowse database.

Data processing for each cancer multi-omics dataset involved selection of tumour samples common across all omics, removal of genes with NA, zero variance and near-zero variance (i.e. genes with unique values in the samples is less than 10% and the ratio of the frequency of the most common value to the frequency of the second most common value is greater than 95:5) from gene expression omics data using caret R package [42] followed by selection of common genes across all omics. When integrating gene expression and copy number data, the presence of genes with small inter-quartile range (IQR) of expression caused a runtime error in the Oncodrive-CIS tool. Therefore, the smallest permissible IQR threshold was identified for each cancer dataset by deleting in a listwise manner until the tool ran without error. The IQR thresholds for mesothelioma, pancreatic cancer, colon cancer and melanoma datasets were 0.90, 0.50, 0.55 and 0.55, respectively. These final datasets were used for all tools integrating copy number and gene expression to perform an unbiased comparison. Further tool-specific processing is outlined in Figure 1.

Datasets used for meta-dimensional integration tool analyses

Meta-dimensional tool analyses were performed using 2 real multi-omics cancer datasets and 16 simulated datasets.

Real datasets

Hepatocellular carcinoma (HPC) dataset: This dataset [43] comprises the sequencing data for primary tumour (Tumour), adjacent normal tissue (Normal) and portal vein tumour thrombosis (PVTT) samples from 20 HPC patients, totalling 60 samples. The mRNA gene expression (GSE77509; measured using Illumina HiSeq 2500), miRNA gene expression (GSE76903; measured using Illumina HiSeq 2500) and probe-level methylation (GSE77269; measured using Illumina HumanMethylation450 BeadChip) data were downloaded from Gene Expression Omnibus database [44]. Quality control included log transformation of miRNA and mRNA expression data and removal of genes or probes with null values in more than 25% of samples. We used inter-sample variance to select the most informative features [45]. The top 10% of the variable mRNA and miRNA gene expression and top 5% of methylation probes were chosen for integration analysis as these features captured most of the variance in the dataset (Supplementary Table S6 and Supplementary Figure S6).

Glioblastoma (GBM) dataset: Protein expression measured using reverse phase protein array technology, gene expression measured using AffyU133a array. DNA methylation data measured using Illumina Infinium HumanMethylation27 platform and phenotype information for glioblastoma tumour samples were downloaded from UCSC Xena database. Common samples across all omics data and having information on the clinical subtype were selected for analysis. Feature selection was based on inter-sample variance, with the top 25% variable genes and probes selected (Supplementary Table S6 and Supplementary Figure S7). The final dataset contained 100 samples belonging to 4 clinical subtypes: Classical (25 samples), Mesenchymal (27 samples), Neural (17 samples) and Proneural (31 samples).

Simulated datasets

The miRNA gene expression data, DNA methylation data and the top 1000 inter-sample variable genes from mRNA gene expression data from the TCGA breast cancer dataset [46] (Supplementary Table S7) were used to create simulated datasets using a previously detailed method [28].

Briefly, four simulated datasets A, B, C and D were created. Each simulated dataset contained three matrices referred to as Omics data 1, Omics data 2 and Omics data 3, simulated with rows corresponding to 60 samples and columns corre-
responding to 500 features. In each simulated matrix, the samples were modelled using Gaussian distributions such that they were equally distributed among three classes (i.e. subtypes). Additionally, independent Gaussian noise (mean = 0, standard deviation = 0.4) was added to the features profiles. The profiles of the features in the samples belonging to each class with added independent noise are given below:

1. \(\text{Normal}(m_i, s_{di}) + \text{Normal}(0,0.4)\)
2. \(\text{Normal}(m_i - m_i/2, s_{di}) + \text{Normal}(0,0.4)\)
3. \(\text{Normal}(m_i + m_i/2, s_{di} + s_{di}/10) + \text{Normal}(0,0.4)\)

where \(m_i\) and \(s_{di}\) are the mean and standard deviation, respectively, calculated from 500 randomly selected features from the real omics data types.

To assess the ability of the tools to combine the patterns identified in individual omics data types, certain classes in two or all of the omics data types of the simulated datasets B, C and D were simulated to be a hidden class (Table 3). Simulated dataset A contained no hidden class. A hidden class contained samples whose feature profiles were similar to that of the samples in the remaining two classes. Presence of such classes in datasets reduces the signal strength thereby making the dataset complex.

To understand the effect of sample size on the performance of these tools, all the datasets were recreated with 150 samples, with each class containing 50 samples. The 150-sample datasets will be referred to as Large Group, while the previously created 60-sample datasets will be referred to as Small Group. To assess the influence of noise, Gaussian noisy features with means equal to that of the genes selected randomly from the real dataset and with a standard deviation of 2 were added to the datasets in both the Small and Large Groups and are referred to as Small Noisy Group and Large Noisy Group, respectively. As these (noisy) features have a constant standard deviation across all three classes, they do not have the information to discriminate the classes and hence, are noisy. For all the datasets, 100 noisy features were added to Omics data 1, while 20 noisy features were added to Omics data 2 and 3.

### Running the multi-omics integration tools

The CNAmet, iGC, PLRS, MethylMix, SNF and BCC tools were run in R on a 64-bit Ubuntu desktop computer. The iClusterPlus and mixOmics tools were also run in R but on a high performance computing Linux cluster hosted by Queensland University of Technology, Brisbane, Australia. The Oncodrive-CIS tool, which is available as a Python script, was executed via the terminal (command line) in Python version 2.7 on a 64-bit Ubuntu desktop. All the tools were run using their default parameter settings obtained from the respective manuals whereas the parameter values for the mixOmics tool were obtained from their case study (http://mixomics.org/mixdiablo/case-study-tcga/). The runtimes of these tools were recorded as the time
taken to execute the integration function in each tool, and the
data pre-processing time prior to running these tools was not
included. We have provided the R code to reproduce the pre-
processing, variable selection, creation of simulated datasets,
running of tools and performance evaluation presented in this
study on GitHub (https://github.com/AtinaSat/Evaluation-of-
integration-tools).

Performance evaluation of multi-staged integration
tools
Due to differences in the omics data types integrated by the
multi-staged tools, separate evaluations were conducted for the
tools integrating copy number and gene expression data
(Oncodrive-CIS, iGC, PLRS and CNAmet tools) and the tools
integrating methylation intensity and gene expression data
(MethylMix and CNAmet tools).

The tools were evaluated based on the overlap estimates of
genes, function terms (GO terms) and pathways with that of gold
standard cancer gene list—cBioPortal cancer gene list (CCGL;
http://www.cbioportal.org/cancer_gene_list.jsp) [47] which con-
tains 981 known cancer genes. To evaluate the reliable predic-
tions from the tools as well as to miss the identified cancer
genes, a maximum of 1500 genes driven by amplification (or
hypomethylation) and a maximum of 1500 genes driven by dele-
tion (or hypermethylation) with FDR values < 0.05 were retained
for each tool. The two lists were combined, and the unique
genes were identified for performance assessment. As the PLRS
tool does not provide the distinction between amplification and
deletion among the results, to ensure tool evaluations were
based on datasets consistent in size, a maximum of 3000 genes
with FDR values < 0.05 were selected for evaluation. Similarly,
the MethylMix tool does not provide the distinction between hyper-
methylation and hypomethylation among the results; hence,
a maximum of 3000 genes with FDR values < 0.05 were selected
for evaluation.

The selected gene result from each tool and the cancer gene
list were enriched with GO terms for Biological Process (BP),
Cellular Component (CC) and Molecular Function (MF) categories
using clusterProfiler R package [48] and the Reactome pathways
[49] using the ReactomePA R package [50]. While the gene-level
evaluation is based on estimating the number of overlapping
genes, the function and pathway level evaluations are based on
estimating the number of overlapping enriched GO function
terms and Reactome pathways, respectively, between the results
and the cancer gene list. Figure 2 outlines the steps for the
selection of genes and evaluation at the gene, function and
pathway levels.

Performance evaluation of meta-dimensional integration
tools
The meta-dimensional tools were evaluated based on the sam-
ple classification performance in various scenarios: (i) binary and
multi-class classification, (ii) presence of hidden classes,
(iii) small and large sample sizes and (iv) noise in small and
large sample sizes. The HPC dataset was used for the binary
classification analysis in which the sample classes were Normal
and PVTT/Tumour, with the latter class formed by merging the
PVTT and Tumour samples. For multi-class classification analy-
sis, the HPC and GBM datasets were used. The sample classes
for the HPC dataset were Normal, PVTT and Tumour, while
for the GBM dataset the classes were Classical, Mesenchymal,
Neural and Proneural. As the mixOmics tool performs super-
vised classification, the samples in both the real and simulated
datasets were divided into training (75%) and test (25%) datasets
prior to analysis. The tool performance was assessed using the
classification results obtained for the test datasets.

The sample classification powers of the meta-dimensional integration tools were assessed using the following metrics:

\[
\text{Precision} = \frac{\text{True positives}}{\text{True positives} + \text{False positives}}
\]

\[
\text{Recall} = \frac{\text{True positives}}{\text{True positives} + \text{False negatives}}
\]

\[
F_1 = \frac{2 \times \text{Precision} \times \text{Recall}}{\text{Precision} + \text{Recall}}
\]

\[
\text{Avg.} F_1 = \frac{\sum_{i=1}^{n} F_{1i}}{n} \quad (n = \text{number of classes})
\]

\[
\text{Accuracy} = \frac{\text{True positives}}{\text{Total number of samples}}
\]

In the following section, we have highlighted the performance of meta-dimensional tools mainly based on their average
F1 scores and accuracies. Refer to Supplementary Tables S9–S12
for precision and recall scores achieved by these tools for the
simulated datasets.

Results
Multi-staged integration tools analyses
Copy number and gene expression integration

The performance of the copy number and gene expression inte-
gration tools in the mesothelioma, pancreatic cancer, colon can-
cer and melanoma datasets were tested at three evaluation
levels: gene, function and pathway. The 3000 most informative
and statistically significant unique genes identified by these
tools were utilized for the evaluations. For these gene lists and
the CCGL, significant GO function terms and pathways were
identified. For each evaluation, overlaps of the results from the
tools with the CCGL in each dataset were identified and are
shown in Table 4. A strong overlap demonstrates high sensitivity
of the tool to identify cancer-associated genes, GO function
terms and pathways. A total of 20 overlap tests were performed
(1 gene, 3 functions and 1 pathway for each of the 4 datasets) for
each tool.

The PLRS tool achieved the highest overlap with CCGL in
11/20 overlap tests, demonstrating the highest sensitivity com-
pared to other tools. The Oncodrive-CIS and iGC tools achieved
the highest overlap in 6/20 and 2/20 tests, respectively. All tools
displayed poor performance for the mesothelioma dataset. The
comparatively small sample size of the mesothelioma dataset
(87 samples) likely reduced the power to identify significant
genes and subsequently the significant GO function terms and
pathways associated with the disease. Overall, all tools showed
an increasing trend in the performance with increasing sample
size of the datasets.

We compared the approaches implemented by these tools
using Venn diagrams of the results at all evaluation levels for
different datasets. High congruence was observed between the
iGC, PLRS and Oncodrive-CIS tools at gene level in the pancreatic
cancer (35–49%), colon cancer (67–74%) and melanoma (60–66%)
datasets (Figure 3). The goal of all tools evaluated is to identify
a statistically significant effect of copy number change on gene
Table 4. Gene, function and pathway level comparisons between multi-staged tools integrating copy number variation and gene expression data and the CCGL. The numbers in parentheses in the heading indicate the number of features identified using CCGL in each category. The numbers in parentheses in the results indicate the percentage of overlapping features with respect to CCGL features. The numbers in bold indicate the highest overlap in each category in a cancer dataset.

| Dataset      | Tools        | Genes Top significant genes | Overlap with CCGL (981) | Functional—BP GO terms for top significant genes | Overlap with CCGL (2649) | Functional—CC GO terms for top significant genes | Overlap with CCGL (118) | Functional—MF GO terms for top significant genes | Overlap with CCGL (232) | Pathways Pathways for top significant genes | Overlap with CCGL (462) | Total number of overlapping features |
|--------------|--------------|----------------------------|-------------------------|-----------------------------------------------|--------------------------|------------------------------------------------|-------------------------|-----------------------------------------------|--------------------------|-----------------------------------------------|----------------------------|--------------------------------------|
| Mesothelioma | CNAmet       | 1997                       | 103 (10.50)             | 0                                              | 0 (0.00)                 | 6                                              | 0 (0.00)                | 0                                              | 0 (0.00)                 | 0                                              | 0 (0.00)                 | 103                                  |
|              | iGC          | 1155                       | 63 (6.42)               | 0                                              | 0 (0.00)                 | 5                                              | 0 (0.00)                | 4                                              | 0 (0.00)                 | 0                                              | 0 (0.00)                 | 63                                   |
|              | PLRS         | 2472                       | 124 (12.64)             | 6                                              | 1 (0.04)                 | 19                                             | 7 (5.93)                | 4                                              | 3 (2.29)                 | 1                                              | 0 (0.00)                 | 135                                  |
|              | Oncodrive-CIS| 663                        | 43 (4.38)               | 0                                              | 0 (0.00)                 | 0                                              | 0 (0.00)                | 0                                              | 0 (0.00)                 | 0                                              | 0 (0.00)                 | 43                                   |
| Pancreatic cancer | CNAmet     | 2824                       | 147 (14.98)             | 17                                             | 11 (0.42)                | 12                                             | 0 (0.00)                | 15                                             | 4 (1.72)                 | 7                                              | 0 (0.00)                 | 162                                  |
|              | iGC          | 2495                       | 138 (14.07)             | 34                                             | 9 (0.34)                 | 11                                             | 5 (4.24)                | 6                                              | 2 (0.86)                 | 3                                              | 0 (0.00)                 | 154                                  |
|              | PLRS         | 3000                       | 180 (18.35)             | 70                                             | 27 (1.02)                | 19                                             | 3 (2.54)                | 32                                             | 13 (5.60)                | 10                                             | 5 (1.08)                 | 228                                  |
|              | Oncodrive-CIS| 2150                      | 122 (12.44)             | 86                                             | 37 (1.40)                | 45                                             | 7 (5.93)                | 35                                             | 14 (6.03)                | 30                                             | 10 (2.16)                | 190                                  |
| Colon cancer | CNAmet       | 2539                       | 146 (14.88)             | 91                                             | 64 (2.42)                | 3                                              | 0 (0.00)                | 2                                              | 0 (0.00)                 | 6                                              | 5 (1.08)                 | 215                                  |
|              | iGC          | 2879                       | 181 (18.45)             | 256                                            | 144 (5.44)               | 92                                             | 22 (18.64)              | 41                                             | 12 (5.17)                | 127                                            | 32 (6.93)                | 391                                  |
|              | PLRS         | 3000                       | 188 (18.16)             | 424                                            | 224 (8.46)               | 135                                            | 27 (22.88)              | 79                                             | 23 (9.91)                | 187                                            | 47 (10.17)               | 509                                  |
|              | Oncodrive-CIS| 2733                      | 165 (16.82)             | 273                                            | 142 (5.36)               | 120                                            | 26 (22.03)              | 73                                             | 18 (7.76)                | 107                                            | 30 (6.49)                | 381                                  |
| Melanoma     | CNAmet       | 2366                       | 140 (14.27)             | 156                                            | 131 (4.93)               | 43                                             | 18 (15.25)              | 7                                              | 1 (0.43)                 | 15                                             | 9 (1.95)                 | 299                                  |
|              | iGC          | 2876                       | 172 (17.53)             | 669                                            | 306 (11.55)              | 249                                            | 42 (35.59)              | 164                                            | 46 (19.83)              | 393                                            | 86 (18.61)               | 652                                  |
|              | PLRS         | 3000                       | 198 (20.10)             | 472                                            | 224 (8.46)               | 224                                            | 43 (36.44)              | 147                                            | 42 (18.10)              | 310                                            | 57 (12.34)               | 564                                  |
|              | Oncodrive-CIS| 2758                      | 181 (18.45)             | 653                                            | 302 (11.40)              | 241                                            | 48 (40.68)              | 158                                            | 52 (22.41)              | 356                                            | 81 (17.53)               | 664                                  |
expression. The iGC tool uses Student’s t-test, PLRS uses piecewise linear regression splines and Oncodrive-CIS uses Z-test. The high similarity between these statistical methods resulted in the observed high overlap of implicated genes. However, in general highest congruence was observed between PLRS and iGC tools (Supplementary Figures S1–S4).

Methylation and gene expression integration
Similar to copy number and gene expression integration tools, methylation and gene expression integration tools were also assessed at three levels—gene, function and pathway. The top 3000 methylation-driven genes were selected from the results provided by the MethylMix and CNAmet tools to perform 20 overlap tests with CCGL. The MethylMix tool, which integrates the omics datasets using a continuous data and linear regression approach, outperformed the CNAmet tool, which integrates using a categorical data and signal-to-noise ratio approach, in 18/20 overlap tests (Table 5). The sharp cut-offs used by CNAmet tool to signify hypermethylated and hypomethylated genes could have led to the misinterpretation of the underlying relationship between methylation intensity and expression of a gene. Venn diagrams of the gene-level results between the tools showed CNAmet genes overlapped on an average of 54.73% with MethylMix genes (Figure 4). Venn diagrams of BP, CC, MF and pathway terms between the tools showed CNAmet results overlapped on an average of 67.29%, 17.85%, 43.2% and 6.88%, respectively, with MethylMix results (Supplementary Figure S5).

Meta-dimensional integration tools analyses

Binary and multi-class classification of HPC dataset
The goal of binary and multi-class classification using meta-dimensional integration is to accurately identify the different tumour subtypes or patient types using multi-omics datasets. Binary classification involves segregating the samples into two subtypes/classes, while multi-class classification involves identifying more than two classes. Tools achieving high accuracies and F1 scores in multi-class classification are preferable as tissue-specific tumours often comprise more than two molecular subtypes that may differ in prognosis and treatment strategies.

The performances of the tools during binary and multi-class classification tested using the HPC and GBM datasets is shown in Table 6. In binary class classification, all tools performed with accuracy > 0.9 except for iClusterPlus tool (0.78). The mixOmics tool outperformed the others in multiple-class classification analyses by providing the highest average F1 scores and accuracies among all the tools. The performance of all the tools was significantly better in the binary classification compared to the multi-class classification analyses. In the former analysis, all the tools were capable of retrieving the two classes with high precision and recall. However, during the multi-class classification using the HPC dataset, only the mixOmics tool could delineate between the samples from Tumour and PVTT classes. The poor precision and recall in classifying between these two classes could have been due to the high heterogeneity in these classes, as reported by Yang et al. [37]. In the GBM dataset, all tools achieved the lowest performance for the Neural subtype compared to the other subtypes. The poor classification of this subtype could be due to the fact that it lacks characteristic gene abnormalities [51] caused likely by normal tissue contamination [52]. Hence, this subtype could be non-tumour-specific phenotype [53]. Multi-class classification of HPC and GBM datasets using the mixOmics tool produced better classification. The prior learning using training data enabled the tool to distinguish better the signals from the different classes, thereby resulting in superior precision and recall scores for all classes. The SNF tool achieved the second best classification in the multi-class classification scenario.

iClusterPlus is a popular integration tool that has been used for multi-omics analysis of numerous cancers [20, 54, 55]. Given the poor performance of iClusterPlus in the binary classification
Table 5. Gene, function and pathway level comparisons between multi-staged tools integrating methylation and gene expression data and the CCGL. The numbers in parentheses in the heading indicate the number of features identified using CCGL in each category. The numbers in parentheses in the results indicate the percentage of overlapping features with respect to CCGL features. The numbers in bold indicate the highest overlap in each category in a cancer dataset.

| Dataset       | Tools  | Genes Top significant genes | Functional—BP GO terms for top significant genes | Functional—CC GO terms for top significant genes | Functional—MF GO terms for top significant genes | Pathways for top significant genes | Total number of overlapping features |
|---------------|--------|-----------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------------|----------------------------------|
| Mesothelioma  | CNAmet | 956 (5.10)                  | 103 (75.283)                                  | 0 (0.00)                                      | 6 (1.43)                                       | 0 (0.00)                        | 126                               |
|               | MethylMix | 2346 (15.29)                | 505 (424.16.01)                               | 42 (11.9.32)                                  | 26 (10.4.31)                                   | 12 (5.1.08)                     | 600                               |
| Pancreatic cancer | CNAmet | 1771 (9.58)                   | 40 (31.1.17)                                   | 0 (0.00)                                      | 5 (3.1.29)                                     | 0 (0.00)                        | 128                              |
|               | MethylMix | 3000 (18.45)                | 614 (425.16.04)                               | 31 (6.5.08)                                   | 13 (6.2.59)                                    | 19 (7.5.12)                     | 625                              |
| Colon cancer  | CNAmet | 1886 (10.30)                  | 21 (13.0.49)                                   | 0 (0.00)                                      | 2 (2.0.86)                                     | 41 (31.6.71)                    | 147                              |
|               | MethylMix | 2156 (12.23)                | 95 (51.1.93)                                   | 16 (2.1.69)                                   | 11 (3.1.29)                                    | 3 (0.00)                        | 176                              |
| Melanoma      | CNAmet | 2826 (13.86)                  | 320 (207.7.81)                                 | 28 (10.8.47)                                  | 16 (3.1.29)                                    | 53 (33.7.14)                    | 389                              |
|               | MethylMix | 2492 (14.17)                | 566 (429.16.19)                                | 63 (14.1.86)                                  | 54 (19.8.19)                                   | 45 (19.4.11)                    | 620                              |
Table 6. Binary and multi-class classification results by meta-dimensional integration tools for HPC and GBM datasets. The numbers in parentheses beside each class indicate the number of samples belonging to the class in the cluster/total number of samples in the cluster.

| Dataset | Metrics/Tools | SNF | BCC | mixOmics | iClusterPlus |
|---------|---------------|-----|-----|----------|-------------|
| HPC—Binary classification | | | | | |
| Classes | Normal (20/23) | PVTT/Tumour (37/37) | Normal (20/24) | PVTT/Tumour (36/36) | Normal (6/7) | PVTT/Tumour (8/8) | Normal (20/33) | PVTT/Tumour (27/27) |
| Precision | 0.87 | 1 | 0.83 | 1 | 0.86 | 1 | 0.61 | 1 |
| Recall | 1 | 0.92 | 1 | 0.9 | 1 | 0.89 | 1 | 0.68 |
| F1 | 0.93 | 0.96 | 0.91 | 0.95 | 0.92 | 0.94 | 0.76 | 0.81 |
| Avg F1 | 0.94 | 0.93 | 0.93 | 0.93 | 0.93 | 0.93 | 0.78 | 0.78 |
| Accuracy | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.78 | 0.78 |
| HPC—Multi-class classification | | | | | |
| Classes | Normal (20/22) | PVTT/Tumour (10/19) | Normal (20/22) | PVTT/Tumour (13/26) | Normal (6/7) | PVTT/Tumour (3/4) | Normal (19/24) | PVTT/Tumour (9/18) |
| Precision | 0.91 | 0.53 | 0.91 | 0.5 | 0.86 | 0.75 | 0.79 | 0.5 |
| Recall | 1 | 0.5 | 1 | 0.3 | 1 | 0.75 | 0.95 | 0.45 |
| F1 | 0.95 | 0.51 | 0.95 | 0.37 | 0.92 | 0.75 | 0.86 | 0.47 |
| Avg F1 | 0.66 | 0.63 | 0.63 | 0.8 | 0.78 | 0.8 | 0.6 | 0.61 |
| Accuracy | 0.67 | 0.65 | 0.65 | 0.8 | 0.78 | 0.8 | 0.6 | 0.61 |
| GBM—Multi-class classification | | | | | |
| Classes | Classical (23/33) | Mesenchymal (17/31) | Neural (0/10) | Pro neural (23/26) | Classical (24/37) | Mesenchymal (1/6) | Neural (0/1) | Pro neural (23/56) | Classical (4/9) | Mesenchymal (8/8) | Neural (2/3) | Pro neural (5/5) | Classical (10/25) | Mesenchymal (13/41) | Neural (0/7) | Pro neural (18/27) |
| Precision | 0.7 | 0.55 | 0.88 | 0.41 | 0.17 | 0.65 | 0.67 | 1 | 0.4 | 0.32 | 0 | 0.67 |
| Recall | 0.82 | 0.71 | 0.74 | 0.86 | 0.04 | 0.74 | 0.73 | 1 | 0.4 | 0.36 | 0.54 | 0 | 0.58 |
| F1 | 0.76 | 0.62 | 0.8 | 0.13 | 0.06 | 0.69 | 0.61 | 0.74 | 0.4 | 0.38 | 0.4 | 0 | 0.62 |
| Avg F1 | 0.55 | 0.22 | 0.48 | 0.74 | 0.76 | 0.74 | 0.74 | 0.41 | 0.35 |
A comparative study of multi-omics integration tools

Figure 3. Congruence between the significant genes identified by CNAmet, iGC, PLRS, Oncodrive-CIS tools (copy number and gene expression integrating tools) and the CCGL genes in the (A) mesothelioma, (B) pancreatic cancer, (C) colon cancer and (D) mesothelioma datasets.

of the HPC dataset, we speculated that the performance might improve if we restricted the methylation dataset to the top 1000 variable probes (variance range: 0.09–0.21) of the methylation dataset. As speculated, iClusterPlus showed improved classification accuracy in both the HPC and GBM datasets for similarly reduced datasets (Supplementary Table S8).

Performance in the presence of hidden classes

Independent analyses of multiple omics data types may identify subtypes that do not conform to one another as a subtype identified in one omics data may be undetectable in another omics data type. Such subtypes are referred to as the hidden classes, and the meta-dimensional tools aim to identify these classes through joint analysis of multi-omics data. The ability of the tools to retrieve a hidden class was tested using datasets A, B, C and D from the Small Group, where all datasets contain 60 samples and no noisy features. The dataset A that contained no hidden classes is simple compared to the other datasets, which are complex due to the presence of hidden classes in two or more omics data types.

The accuracies obtained by the tools for these datasets are shown in Figure 5A. Across all datasets, the performance of the tools was most accurate for dataset A. For the datasets A and C, the iClusterPlus tool obtained the highest accuracies (1 and 0.6, respectively), while for datasets B and D the mixOmics tool achieved the highest accuracies (0.87 and 0.67, respectively), as compared to the other tools.

The F1 scores achieved by these tools for individual classes in each dataset provide insights into the identification of the classes. A high F1 score, particularly for a hidden class, implies effective combining of shared and complementary subtype information from multiple omics data types to retrieve the underlying class. Our results showed that the recoverability of a hidden class by the tools was lower in comparison to a class that was not hidden. For example, the $F_1$ scores achieved by the tools
Figure 4. Congruence between the significant genes identified by CNAmet, MethylMix tools (methylation and gene expression integrating tools), and the CCGL genes in the (A) mesothelioma, (B) pancreatic cancer, (C) colon cancer and (D) melanoma datasets.

for Class 1 in datasets B and D were lower than that in datasets A and C (Figure 5B). The tools were more susceptible to missing the identification of a class when the class was simulated as a hidden class in more than one omics data type. In datasets C and D, Class 2 was simulated as a hidden class in two and one omics data types, respectively. All tools failed to identify Class 2 ($F_1$ score < 0.5) in dataset C. However, in dataset D, the SNF and mixOmics tools were capable of identifying this class ($F_1$ score > 0.5). For dataset D, which contained non-overlapping hidden classes in all three omics data types, only the mixOmics tool retrieved all three classes ($F_1$ > 0.5), while the SNF and iClusterPlus tools retrieved two out of the three classes. The BCC tool performed the worst for complex datasets, such as datasets C and D, producing only a single cluster solution where all samples belonged to one class.

Accuracy of tools in small and large sample sizes

The influence of sample size on the performance of the tools was assessed by comparing their performances using datasets from Small and Large Groups. Both groups contain the A, B, C and D datasets but differ only by sample size. The Small Group contains datasets with 60 samples whereas the Large Group contains datasets with 150 samples. The iClusterPlus and mixOmics tools accomplished more accurate classifications in the majority of datasets compared to SNF and BCC tools in the Large Group (Figure 6). When comparing the accuracies achieved by these tools for each dataset in Small and Large Groups, BCC, iClusterPlus and mixOmics tools showed improved classification accuracies for datasets in Large Group (Figures 5A and 6). Contrary to the other tools, the SNF tool displayed decreased classification performances for the majority of Large Group datasets. Lack of optimization of parameter settings for large sample sizes such as the number of neighbours while constructing the affinity graphs and number of iterations for fusing multiple networks may have contributed to the decreased performance of this tool.

Performance in the presence of noise

As noise is inherent in biological data, it is crucial to identify the robustness of the selected classifiers while processing noisy data. To test the robustness of these tools, we recreated the A, B, C and D datasets in Small and Large Groups with noisy features and referred to as Small Noisy Group and Large Noisy Group, respectively. Gaussian noisy features (mean = 0 and standard deviation = 2) were added to each of the omics data types in the datasets. As noisy features do not have profiles similar to that of the informative features, their presence confounds the classification process. A good classifier identifies the underlying classification despite the noisy features.
A comparative study of multi-omics integration tools

Figure 5. Performance results of meta-dimensional integration tools for datasets A–D in Small Group. (A) Accuracy measures and (B) $F_1$ scores for individual classes. iCP – iClusterPlus.

Figure 6. Accuracies achieved by the meta-dimensional integration tools for datasets A–D in Large Group. iCP – iClusterPlus.

First, we compared the accuracies achieved by the tools for the datasets in Small Group and Small Noisy Group (Figure 7A). The SNF, BCC and mixOmics tools showed reduced average $F_1$ scores for datasets in the Small Noisy Group compared to that in the Small Group, demonstrating the lack of robustness to noise in these tools. The mixOmics tool was the most affected by the presence of noise compared to the other tools by showing the highest decrease of 43.75% for dataset C.

Next, we tested the influence of noise on these tools when noise was present in larger datasets by using the datasets in Large Group and Large Noisy Group. Contrary to the performance of the tools in small sample size datasets, they exhibited increased robustness as the sample size was increased. The decreases in the average $F_1$ scores of all the tools for datasets in Large Noisy Group compared to that in Large Group were minimal or non-existent (Figure 7B). The presence of increased signal in these datasets may have contributed to the better performances. Overall, the iClusterPlus tool was the most resistant to noise, exhibiting no decrease in the performance in almost all the datasets with small and large sample sizes.

Runtime of multi-staged and meta-dimensional integration tools

Given the large-scale sample availability and genome-wide sequencing of tens of thousands of genes, a trade-off between runtime and performance is highly desirable in a multi-omics integration tool. The runtime was recorded as the time taken to run the integration functions in each tool (Supplementary...
Tables S13 and S14). Among the multi-staged tools, Oncodrive-CIS took the longest time, followed by CNAmet. The iGC and MethylMix tools required less than a minute to complete the analysis. The PLRS, iGC and MethylMix tools were the more user-friendly of the multi-staged tools requiring minimal pre-processing and allowing for easy execution of functions. Among the meta-dimensional tools, iClusterPlus took the longest time, an average of 35 hours for the real datasets and 35 minutes for the simulated datasets. The SNF tool performed the meta-dimensional integration in less than 1 minute. The BCC and SNF tools were easy to execute as these tools had straightforward functions requiring minimal steps. In contrast, running the iClusterPlus and mixOmics tools involved numerous steps, and user intervention was required to assess the results from each of the steps.

Discussion

Our comparative study assessed the performance of five multi-staged and four meta-dimensional integration tools. These tools were designed to facilitate two common objectives for integrative analyses of cancer datasets: (i) identification of cancer driver genes and (ii) tumour subtype discovery or patient/sample classification.

In general, a multi-omics integration study encompasses the following steps: feature selection (optional), selection of an integration tool, processing of input data to fit the tool specifications, running the tool with optimized parameter settings, filtering the output (optional) and finally, interpretation of results. Identification of an optimal integration tool will minimize the challenges encountered at different steps and hence enable researchers to meet the integration objectives. Assessing the performance of the tools in identifying the cancer-associated genes, functions and pathways, and classification of tumour samples, are critical factors to be considered while choosing an efficient tool.

For multi-staged integration studies which seek to identify the cancer driving genes, our comparisons revealed that regression-based integration methods are most effective, identifying most cancer-associated genes, GO terms and pathways. For such analyses, we therefore recommend the PLRS and MethylMix tools as they implement regression-based integration and outperformed the other tools compared in this study. The regression-based integration approaches, which utilize continuous values for copy number or methylation...
status, prevent the loss of information due to the use of non-integer or sharp cut-off values. Using ordinal values can lead to reduced variability between the samples and hence miss the true relationship between the omics datasets analysed [56]. Cancer is a highly heterogeneous disease, and the use of ordinal values cannot accurately account for the differences in the degree of aberration among the samples and thus may not be optimal for integrative analyses [57].

As multi-staged integration tools focus on cis interactions between gene expression and copy number/methylation of genes and many cancer genes are implicated in the disease through multiple mechanisms, it is possible to miss the cancer genes in the tool results if small cut-offs, such as top 200 [58], are used. In order to not miss the identification of these cancer genes, we used a liberal cut-off that is larger than the number of the gold standard genes. While our assessment was restricted to the top 3000 most significant and informative genes, the performance of the tools was consistent when gene-level analysis was performed for top 1000 and top 2000 most significant genes (Supplementary Table S2). Users may also select genes based on the scores specific to each tool [15].

Our analyses also revealed potential for low precision of multi-staged integration tools [27]. Prior to the selection of the top 3000 significant genes from the output, in majority of the datasets, the PLRS predicted more than 8000 genes to have an association between copy number and gene expression (Supplementary Table S3). As multi-staged integration involves multiple testing, in order to reduce the false positives and prevent the loss of statistical power, we recommend either feature selection prior to integration or filtering down the output after integration.

To potentially improve the accuracy in identification of the true associations, we recommend the tools that utilize additional biological information during integration. The PLRS tool (the best performing method) uses both segmented copy number and thresholded copy number, as well as call probabilities when available. These data provide information on the heterogeneity among the samples as well as the precision of the copy number call, leading to the identification of statistically reliable associations that drive cancer [57]. Use of normal samples, when possible, may also add more reliability to the identified genes. For example, the use of normal samples allows the MethylMix tool to detect genes for which expression is not only regulated by methylation but also differentially methylated in comparison to normal samples [59]. A drawback common to all the multi-staged integration tools used in this study is that they model only the cis relationship between copy number or methylation and gene expression of genes and do not address the trans relationship, which is the regulation of distant genes, as has been reported in many studies [60, 61].

To classify the cancer subtypes using meta-dimensional integration, we recommend the mixOmics tool as it provided the most accurate classifications for the majority of the real and simulated datasets. Alternatively, when the sample labels are not known prior to integration, we recommend iClusterPlus as it provided most accurate classification for the majority of the simulated datasets. However, it should be noted that the performance of iClusterPlus tool can reduce in the presence of a large number of uninformative features (as seen for the real HPC and GBM datasets). Hence, feature selection prior to integration is critical. The iClusterPlus tool is also computationally intensive, and the runtime increases with an increase in the number of input features. A recent version of the iClusterPlus tool, iClusterBayes [62], endeavours to overcome these challenges using a Bayesian integrative clustering approach. The SNF tool may also be considered due to its enhanced performance in the real datasets, and its performance could potentially improve further by optimizing parameter settings [28]. However, the low accuracy of all the meta-dimensional tools in multi-class classification scenario (≤0.8) shows that improved integration approaches are needed.

An important characteristic of a good meta-dimensional integrative tool is to identify the subtypes that are common or unique to different omics datasets and effectively link this information to provide the best classification. Our study showed that the meta-dimensional tools have difficulties in identifying a class that is unidentifiable in the majority of the omics data types used for integration and classification. For the Tumour and PVT classes in the HPC dataset and Neural class in GBM dataset, which are not clearly distinguished in the omics data types [43], all tools except mixOmics failed to retrieve these classes. Similarly, all tools showed low precision and recall scores for Class 2 in simulated dataset C in the Small Group, as this class was identifiable in only one of the three omics data types. When integrating such complex datasets, use of a tool that employs a supervised approach such as the mixOmics tool may provide better classification results as seen in the analysis with the real datasets and simulated dataset D. To estimate the complexity of the datasets and their influence on integration results, Tini et al. [28] recommends analysis and visualization of independent omics data types using techniques such as PCA to quantify the signal and subtypes present in them.

Our analyses showed that noise can have a substantial negative impact on the classification. Hence, use of advanced feature selection techniques is critical [63] prior to integration. Given, small sample sizes (~20 samples per class) and the presence of noise negatively impact the performance of these tools, use of larger sample sizes generally improves their performance due to the presence of higher amounts of signal relative to noise. However, due to the high dimensionality of these datasets, combined with heterogeneity in the samples, it is important to perform an initial power calculation to ensure sufficient sample sizes are analysed [64]. In datasets with a small number of noisy features, the iClusterPlus tool is preferable as the integrative results were least affected by noisy features.

Limitations

All tools were run using default parameters to avoid bias. However, optimization of the parameters might have improved the performance of the tools, such as the SNF tool [28]. Only continuous data were used to assess the performance of meta-dimensional integrative tools. The iClusterPlus, mixOmics and SNF tools are also capable of integrating heterogeneous data, such as binary and categorical data types, and additional analyses are required to assess their performance when integrating such data. Our assessment does not fully reflect all the functional aspects of the tools. For instance, the CNAmet tool also includes quantification of the combined effect of copy number and methylation on gene expression, and the iClusterPlus and mixOmics tools can identify the features responsible for the classification; such functionalities were not assessed in the study. Cancer driver genes can be classified as protein-coding or non-coding. In our multi-staged analyses, due to the low number of non-coding genes in the input datasets (≤3%) and the gold standard cancer gene list (≤1%) (Supplementary Table S5), we could not accurately investigate the specific performance of the tools for non-coding genes.
Conclusions

Our results provide much needed advice regarding selection and use of multi-omics integration tools. Tools implementing the regression-based approach for multi-staged integration effectively capture the association between the omics data types. The potential for false positive findings from multi-staged integration can be minimized using control datasets, feature selection prior to integration and/or filtering down the output after integration. For the meta-dimensional integration tools, the use of larger sample sizes enables more accurate identification of tumour and patient groups as well as diminishing the adverse effect of noise. Additional factors such as feature selection and parameter optimization are also critical and can improve the integration for both multi-staged and meta-dimensional integration tools. Although the multi-omics tools investigated improved the classification and feature identification that were undetectable in some individual omics data types, they still have much room for improvement with respect to their performance and ease of use.

Key Points

- Multi-staged and meta-dimensional integration of multi-omics data achieve cancer driver gene identification and tumour subtyping, respectively.
- Regression-based approaches, such as the PLRS and MethylMix tools, provide more effective multi-staged integration due to their use of continuous values for copy number and methylation status.
- The mixOmics and iClusterPlus tools, which employ matrix factorization for meta-dimensional integration, showed superior classification compared to the other tools in real and simulated datasets.
- Prior feature selection and sufficient sample size are critical for effective multi-omics integration.

Supplementary Data

Supplementary data are available online at https://academic.oup.com/bib.

Acknowledgements

We would like to thank Shraddha Tumsi for useful discussions and computational support.

Funding

Advance Queensland Research Fellowship (to S.H.N.) and Postgraduate Scholarship from the School of Biomedical Sciences at Queensland University of Technology (to A.S.).

References

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
2. Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013;45:1134–40.
3. Baylin SB. DNA methylation and gene silencing in cancer. Nat Rev Clin Oncol 2005;2:S4–S11.
4. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719.
5. Lee S, Stewart S, Nagtegaal I, et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res 2012;72:4574–86.
6. List M, Haushchild A-C, Tan Q, et al. Classification of breast cancer subtypes by combining gene expression and DNA methylation data. J Integr Bioinform 2014;11:1–14.
7. Hoadley KA, Yau C, Wolf DM, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014;158:929–44.
8. International Cancer Genome Consortium. International network of cancer genome projects. Nature 2010;464:993–8.
9. Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) 2015;19:A68–A77.
10. Ritchie MD, Holzinger ER, Li R, et al. Methods of integrating data to uncover genotype-phenotype interactions. Nat Rev Genet 2015;16:85–97.
11. Crick F. Central dogma of molecular biology. Nature 1970;227:561.
12. Louhimori R, Hautaniemi S. CNAmet: an R package for integrating copy number, methylation and expression data. Bioinformatics 2011;27:887–8.
13. Lai Y-P, Wang L-R, Wang W-A, et al. iGC—an integrated analysis package of gene expression and copy number alteration. BMC Bioinformatics 2017;18:35.
14. Leday GG, van de Wiel MA. PLRS: a flexible tool for the joint analysis of DNA copy number and mRNA expression data. Bioinformatics 2013;29:1081–2.
15. Tamborero D, Lopez-Bigas N, Gonzalez-Perez A. OncodriveCIS: a method to reveal likely driver genes based on the impact of their copy number changes on expression. PLoS One 2013;8:e55489.
16. Gøvaert O. MethylMix: an R package for identifying DNA methylation-driven genes. Bioinformatics 2015;31:1839–41.
17. Shapiro JA. Revisiting the central dogma in the 21st century. Ann N Y Acad Sci 2009;1178:6–28.
18. Curtis C, Shah SP, Chin S-F, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346–52.
19. Mo Q, Wang S, Sehans VE, et al. Pattern discovery and cancer gene identification in integrated cancer genomic data. PNAS 2013;110:4245–50.
20. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543.
21. Fujita N, Mizuarai S, Murakami K, et al. Biomarker discovery by integrated joint non-negative matrix factorization and pathway signature analyses. Sci Rep 2018;8:9743.
22. Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell 2018;173:321–37.
23. Wang B, Mezlini AM, Demir F, et al. Similarity network fusion for aggregating data types on a genomic scale. Nat Methods 2014;11:333–7.
24. Lock EF, Dunson DB. Bayesian consensus clustering. Bioinformatics 2013;29:2610–6.
25. Mo Q, Shen R. iClusterPlus: Integrative clustering of multi-type genomic data. R package version 1.14.0., 2016; (August 2019, date last accessed).
26. Rohart F, Gautier B, Singh A, et al. mixOmics: an R package for ‘omics feature selection and multiple data integration. PLoS Comput Biol 2017;13:e1005752.
27. Louhimo R, Lepikhova T, Monni O, et al. Comparative analysis of algorithms for integration of copy number and expression data. Nat Methods 2012;9:351.
28. Tini G, Marchetti L, Priami C, et al. Multi-omics integration—A comparison of unsupervised clustering methodologies. Brief Bioinform 2017;16:71–11.
29. Pucher BM, Zeleznik OA, Thallinger GG. Comparison and evaluation of integrative methods for the analysis of multilevel omics data: a study based on simulated and experimental cancer data. Brief Bioinform 2018;20:671–81.
30. Leday GG, van der Vaart AW, van Wieringen WN, et al. Modeling association between DNA copy number and gene expression with constrained piecewise linear regression splines. Ann Appl Stat 2013;7:823–45.
31. Huang S, Chaudhary K, Garmire LX. More is better: recent progress in multi-omics data integration methods. Front Genet 2017;8:94.
32. Bersanelli M, Mosca E, Remondini D, et al. Methods for the integration of multi-omics data: mathematical aspects. BMC Bioinformatics 2016;17:167–77.
33. Pearl J. Probabilistic Reasoning in Intelligent Systems: Networks of Plausible Inference. Morgan Kaufmann Publishers, 1988.
34. Tibshirani R. Regression shrinkage and selection via the lasso. J Roy Stat Soc B Stat Methodology 1996;58:267–88.
35. Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 2018;8:1548–65.
36. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330–7.
37. Raphael BJ, Hruban RH, Aguirre AJ, et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 2017;32:185–203.
38. Akbani R, Akdemir KC, Aksoy BA, et al. Genomic classification of cutaneous melanoma. Cell 2015;161:1681–96.
39. Goldman M, Craft B, Zhu J, et al. The UCSC Xena platform for public and private cancer genomics data visualization and interpretation. bioRxiv Preprint. 2019;326470.
40. Mermel CH, Schumacher SE, Hill B, et al. GISTIC2.0 Facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011;12:R41.
41. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 2011;12:323.
42. Kuhn M. Building predictive models in R using the caret package. J Stat Softw 2008;28:1–26.
43. Yang Y, Chen L, Gu J, et al. Recurrently deregulated lncRNAs in hepatocellular carcinoma. Nat Commun 2017;8:14421.
44. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207–10.
45. Liu JJ, Cutler G, Li W, et al. Multiclass cancer classification and biomarker discovery using GA-based algorithms. Bioinformatics 2005;21:2691–7.
46. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61–70.
47. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401–4.
48. Yu G, Wang L-G, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012;16:284–7.
49. Fabregat A, Sidireopoulos K, Garapati P, et al. The reactome pathway knowledgebase. Nucleic Acids Res 2015;44:D481–7.
50. Yu G, He Q-Y. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst 2016;12:477–9.
51. Brennan CW, Verhaar AG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462–77.
52. Gill BJ, Pisapia DJ, Malone HR, et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. PNAS 2014;111:12550–5.
53. Wang Q, Hu B, Hu X, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 2017;32:42–56 e6.
54. Ally A, Balasundaram M, Carlsen R, et al. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017;169:1327–41 e23.
55. Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature 2017;541:169.
56. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006;332:1080.
57. van Wieringen WN, van de Wiel MA. Nonparametric testing for DNA copy number induced differential mRNA gene expression. Biometrics 2009;65:19–29.
58. Lahti L, Schäfer M, Klein H-U, et al. Cancer gene prioritization by integrative analysis of mRNA expression and DNA copy number data: a comparative review. Brief Bioinform 2012;14:27–35.
59. Gevaert O, Tibshirani R, Plevritis SK. Pancancer analysis of DNA methylation-driven genes using MethylMix. Genome Biol 2015;16:17.
60. Lee H, Kong SW, Park PJ. Integrative analysis reveals the direct and indirect interactions between DNA copy number aberrations and gene expression changes. Bioinformatics 2008;24:889–96.
61. Aran D, Sabato S, Hellman A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol 2013;14:R21.
62. Mo Q, Shen R, Guo C, et al. A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics 2017;19:71–86.
63. Meng C, Zeleznik OA, Thallinger GG, et al. Dimension reduction techniques for the integrative analysis of multi-omics data. Brief Bioinform 2016;17:628–41.
64. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol 2017;18:83.